Active ingredient
Adalimumab NDC Codes
Adalimumab is an active ingredient in 47 finished products listed with the FDA, under 6 names.
Overview
Each product below links to its own NDC page with package NDCs in 10- and 11-digit form.
- Brand and generic names
- Amjevita, Hyrimoz, Hadlima, Adalimumab, Yusimry, Adalimumab-bwwd
- Labelers
- Cordavis Limited, Amgen, Inc, Sandoz Inc, Amgen USA Inc., Organon LLC, Nuvaila Limited, A-S Medication Solutions, Meitheal Pharmaceuticals Inc., Coherus BioSciences Inc
- Strengths
- Adalimumab 40 mg/.4mL; Adalimumab 40 mg/.8mL; Adalimumab 80 mg/.8mL; Adalimumab 20 mg/.2mL; Adalimumab 10 mg/.1mL; Adalimumab 10 mg/.2mL; Adalimumab 20 mg/.4mL
- Dosage forms
- Injection, Solution, Injection, Solution
- Routes
- Subcutaneous
- Drug classes (FDA established)
- Tumor Necrosis Factor Blocker
- HCPCS / J-code
- J0135 — Injection, adalimumab, 20 mg
- Package NDCs
- 65
NDC codes
Newest listings first. Each row links to the product’s NDC page.
| Product | Strength | Form · route | Labeler | Product NDC | Package NDCs (11-digit) | HCPCS |
|---|---|---|---|---|---|---|
| Adalimumab-bwwd | Adalimumab 40 mg/.4mL | SolutionSubcutaneous | Cordavis Limited | 83457-186 | 83457-0186-01 | J0135 |
| Adalimumab-bwwd | Adalimumab 40 mg/.4mL | SolutionSubcutaneous | Cordavis Limited | 83457-187 | 83457-0187-01 | J0135 |
| Adalimumabadalimumab-adaz | Adalimumab 10 mg/.1mL | Injection, SolutionSubcutaneous | Sandoz Inc | 61314-391 | 61314-0391-64 | J0135 |
| Adalimumabadalimumab-adaz | Adalimumab 80 mg/.8mL | Injection, SolutionSubcutaneous | Sandoz Inc | 61314-325 | 61314-0325-20 | J0135 |
| Amjevitaadalimumab-atto | Adalimumab 20 mg/.2mL | InjectionSubcutaneous | Nuvaila Limited | 84612-399 | 84612-0399-01 | J0135 |
| Amjevitaadalimumab-atto | Adalimumab 40 mg/.4mL | InjectionSubcutaneous | Nuvaila Limited | 84612-479 | 84612-0479-0184612-0479-02 | J0135 |
| Amjevitaadalimumab-atto | Adalimumab 80 mg/.8mL | InjectionSubcutaneous | Nuvaila Limited | 84612-481 | 84612-0481-0184612-0481-02 | J0135 |
| Amjevitaadalimumab-atto | Adalimumab 40 mg/.4mL | InjectionSubcutaneous | Nuvaila Limited | 84612-482 | 84612-0482-0184612-0482-02 | J0135 |
| Adalimumabadalimumab-adaz | Adalimumab 20 mg/.2mL | Injection, SolutionSubcutaneous | Sandoz Inc | 61314-332 | 61314-0332-64 | J0135 |
| Amjevitaadalimumab-atto | Adalimumab 20 mg/.2mL | InjectionSubcutaneous | Amgen USA Inc. | 72511-399 | 72511-0399-01 | J0135 |
| Amjevitaadalimumab-atto | Adalimumab 40 mg/.4mL | InjectionSubcutaneous | Amgen USA Inc. | 72511-479 | 72511-0479-02 | J0135 |
| Hyrimozadalimumab-adaz | Adalimumab 80 mg/.8mL | Injection, SolutionSubcutaneous | Cordavis Limited | 83457-107 | 83457-0107-01 | J0135 |
| Hyrimozadalimumab-adaz | Adalimumab 20 mg/.2mL | Injection, SolutionSubcutaneous | Cordavis Limited | 83457-108 | 83457-0108-01 | J0135 |
| Hyrimozadalimumab-adaz | Adalimumab 80 mg/.8mL | Injection, SolutionSubcutaneous | Cordavis Limited | 83457-113 | 83457-0113-01 | J0135 |
| Hyrimozadalimumab-adaz | Adalimumab 40 mg/.4mL | Injection, SolutionSubcutaneous | Cordavis Limited | 83457-100 | 83457-0100-01 | J0135 |
| Hyrimozadalimumab-adaz | Adalimumab 40 mg/.4mL | Injection, SolutionSubcutaneous | Cordavis Limited | 83457-101 | 83457-0101-01 | J0135 |
| Hyrimozadalimumab-adaz | Adalimumab 40 mg/.8mL | Injection, SolutionSubcutaneous | Cordavis Limited | 83457-102 | 83457-0102-01 | J0135 |
| Hyrimozadalimumab-adaz | Adalimumab 40 mg/.8mL | Injection, SolutionSubcutaneous | Cordavis Limited | 83457-103 | 83457-0103-01 | J0135 |
| Amjevitaadalimumab-atto | Adalimumab 20 mg/.2mL | InjectionSubcutaneous | Amgen, Inc | 55513-399 | 55513-0399-01 | J0135 |
| Amjevitaadalimumab-atto | Adalimumab 40 mg/.4mL | InjectionSubcutaneous | Amgen, Inc | 55513-479 | 55513-0479-0155513-0479-02 | J0135 |
| Amjevitaadalimumab-atto | Adalimumab 80 mg/.8mL | InjectionSubcutaneous | Amgen, Inc | 55513-480 | 55513-0480-0155513-0480-02 | J0135 |
| Amjevitaadalimumab-atto | Adalimumab 80 mg/.8mL | InjectionSubcutaneous | Amgen, Inc | 55513-481 | 55513-0481-0155513-0481-02 | J0135 |
| Amjevitaadalimumab-atto | Adalimumab 40 mg/.4mL | InjectionSubcutaneous | Amgen, Inc | 55513-482 | 55513-0482-0155513-0482-02 | J0135 |
| Amjevitaadalimumab-atto | Adalimumab 80 mg/.8mL | InjectionSubcutaneous | Amgen USA Inc. | 72511-481 | 72511-0481-02 | J0135 |
| Amjevitaadalimumab-atto | Adalimumab 40 mg/.4mL | InjectionSubcutaneous | Amgen USA Inc. | 72511-482 | 72511-0482-0172511-0482-02 | J0135 |
| Adalimumabadalimumab-adaz | Adalimumab 40 mg/.4mL | Injection, SolutionSubcutaneous | Sandoz Inc | 61314-327 | 61314-0327-2061314-0327-64 | J0135 |
| Hyrimozadalimumab-adaz | Adalimumab 80 mg/.8mL | Injection, SolutionSubcutaneous | Sandoz Inc | 61314-454 | 61314-0454-2061314-0454-3661314-0454-68 | J0135 |
| Hyrimozadalimumab-adaz | Adalimumab 40 mg/.4mL | Injection, SolutionSubcutaneous | Sandoz Inc | 61314-473 | 61314-0473-2061314-0473-6461314-0473-92 | J0135 |
| Hyrimozadalimumab-adaz | Adalimumab 20 mg/.2mL | Injection, SolutionSubcutaneous | Sandoz Inc | 61314-476 | 61314-0476-64 | J0135 |
| Hyrimozadalimumab-adaz | Adalimumab 10 mg/.1mL | Injection, SolutionSubcutaneous | Sandoz Inc | 61314-509 | 61314-0509-64 | J0135 |
| Hadlimaadalimumab-bwwd | Adalimumab 40 mg/.8mL | SolutionSubcutaneous | A-S Medication Solutions | 50090-6705 | 50090-6705-00 | J0135 |
| Hadlimaadalimumab-bwwd | Adalimumab 40 mg/.8mL | SolutionSubcutaneous | A-S Medication Solutions | 50090-6706 | 50090-6706-00 | J0135 |
| Hadlimaadalimumab-bwwd | Adalimumab 40 mg/.4mL | SolutionSubcutaneous | A-S Medication Solutions | 50090-6707 | 50090-6707-00 | J0135 |
| Hadlimaadalimumab-bwwd | Adalimumab 40 mg/.8mL | SolutionSubcutaneous | Organon LLC | 78206-183 | 78206-0183-01 | J0135 |
| Hadlimaadalimumab-bwwd | Adalimumab 40 mg/.8mL | SolutionSubcutaneous | Organon LLC | 78206-184 | 78206-0184-01 | J0135 |
| Hadlimaadalimumab-bwwd | Adalimumab 40 mg/.8mL | SolutionSubcutaneous | Organon LLC | 78206-185 | 78206-0185-01 | J0135 |
| Hadlimaadalimumab-bwwd | Adalimumab 40 mg/.4mL | SolutionSubcutaneous | Organon LLC | 78206-186 | 78206-0186-01 | J0135 |
| Hadlimaadalimumab-bwwd | Adalimumab 40 mg/.4mL | SolutionSubcutaneous | Organon LLC | 78206-187 | 78206-0187-0178206-0187-59 | J0135 |
| Yusimryadalimumab-aqvh | Adalimumab 40 mg/.8mL | Injection, SolutionSubcutaneous | Meitheal Pharmaceuticals Inc. | 71288-815 | 71288-0815-81 | J0135 |
| Yusimryadalimumab-aqvh | Adalimumab 40 mg/.8mL | Injection, SolutionSubcutaneous | Meitheal Pharmaceuticals Inc. | 71288-816 | 71288-0816-81 | J0135 |
| Yusimryadalimumab-aqvh | Adalimumab 40 mg/.8mL | Injection, SolutionSubcutaneous | Coherus BioSciences Inc | 70114-210 | 70114-0210-02 | J0135 |
| Yusimryadalimumab-aqvh | Adalimumab 40 mg/.8mL | Injection, SolutionSubcutaneous | Coherus BioSciences Inc | 70114-220 | 70114-0220-02 | J0135 |
| Amjevitaadalimumab-atto | Adalimumab 10 mg/.2mL | InjectionSubcutaneous | Amgen, Inc | 55513-413 | 55513-0413-01 | J0135 |
| Amjevitaadalimumab-atto | Adalimumab 40 mg/.8mL | InjectionSubcutaneous | Amgen, Inc | 55513-400 | 55513-0400-0155513-0400-0255513-0400-91 | J0135 |
| Amjevitaadalimumab-atto | Adalimumab 40 mg/.8mL | InjectionSubcutaneous | Amgen, Inc | 55513-410 | 55513-0410-0155513-0410-02 | J0135 |
| Amjevitaadalimumab-atto | Adalimumab 20 mg/.4mL | InjectionSubcutaneous | Amgen, Inc | 55513-411 | 55513-0411-01 | J0135 |
| Amjevitaadalimumab-atto | Adalimumab 40 mg/.8mL | InjectionSubcutaneous | Amgen USA Inc. | 72511-400 | 72511-0400-0172511-0400-02 | J0135 |
Adalimumab: common questions
- Which drugs contain Adalimumab?
- Amjevita, Hyrimoz, Hadlima, Adalimumab, Yusimry, Adalimumab-bwwd.
- Is there a J-code for Adalimumab?
- Med-Code's HCPCS directory matches J0135 to these products. NDC vs J-code.
- Which NDC goes on a claim?
- The package NDC of what was given, in 11-digit form. How to convert a 10-digit NDC.